GE HealthCare Technologies (GEHC) Earnings Analysis
GE HealthCare Technologies (GEHC) next reports earnings on 2026-07-29, consensus EPS 1.04 USD. Last quarter (2026-04-29) it missed with EPS 0.99 USD vs 1.04 USD est (-4.8%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 18.61.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GEHC next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 1.04 USD |
| Revenue estimate | 5.26B |
GEHC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-29 | 0.99 USD | 1.04 USD | -4.8% | Miss |
| 2026-02-04 | 1.44 USD | 1.4 USD | +2.9% | Beat |
| 2025-10-29 | 1.07 USD | 1.05 USD | +1.9% | Beat |
| 2025-04-30 | 1.01 USD | 0.914 USD | +10.5% | Beat |
| 2025-02-13 | 1.45 USD | 1.26 USD | +15.1% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
GEHC valuation and analyst view
| Trailing P/E | 18.61 |
|---|---|
| Trailing EPS | 3.3 USD |
| Price / book | 2.62 |
| Dividend yield | 0.23% |
| Market cap | 28.03B |
| Analyst consensus | Buy (10 buy / 8 hold / 0 sell) |
| Avg price target | 74.9 USD |
Related research pages
Frequently asked questions
When is GE HealthCare Technologies (GEHC)'s next earnings date?
GE HealthCare Technologies is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 1.04 USD and revenue estimate of 5.26B.
Did GEHC beat earnings last quarter?
In its 2026-04-29 report, GEHC posted EPS of 0.99 USD versus a 1.04 USD estimate — a miss of 4.8%.
What is GEHC's earnings track record?
Over the last 5 reported quarters with consensus data, GEHC beat estimates 4 times (80%).
What is GEHC's current P/E ratio and EPS?
GEHC trades at a trailing P/E of 18.61 on trailing EPS of 3.300438596491228 USD.
What do analysts rate GEHC?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 10 buy, 8 hold, 0 sell, 0 strong sell). Average 12-month price target: 74.9 USD.